Tirzepatide 40mg (R&D Only)

What is Tirzepatide?

(Mounjaro, but with a different brand name)

Tirzepatide is one of the most effective GLP-1 research peptides available today.
Alluvi supplies it in pre-filled research pens for easy and controlled use in R&D settings. Each pen is designed for stability, precision multi-dosing, and reliability.

Every pen comes pre-filled and is multi-dose, allowing researchers to set measured doses without any complicated reconstitution.

Choosing Between 20mg & 40mg Pens

The 20mg or 40mg value refers to the total amount of Tirzepatide inside each pen.
To determine which is best for your research, calculate your total required doses — for example:
2.5mg for 4 weeks and 5mg for 2 weeks would equal 20mg in total.

20mg Tirzepatide Pen – Best for early-stage research or gradual titration:

• Suitable for 2.5mg and 5mg research doses.

• Typically provides around an 8-week supply.

40mg Tirzepatide Pen – For advanced or ongoing studies:

• Supports 2.5mg, 5mg, 7.5mg, and 10mg research doses.

• Provides approximately 12–16 weeks of supply, depending on the dosing protocol.

Switching from Mounjaro (MJ)?

If you’re already conducting research using MJ, you can continue with the same dose when switching to Alluvi Tirzepatide.
No restart or re-titration is necessary.

Why Choose Alluvi Pens?

• Multi-dose precision: Simply turn the nozzle to select the desired dose — no guesswork.

• Stability: Buffered and stored correctly to maintain compound integrity.

• Ease of use: Pre-filled and sealed format ensures lab consistency and minimal handling.

Pro Tip

Allow the pen to reach room temperature before research use.
Cold liquid can cause discomfort during injection studies.

Summary

• 20mg Pen → Ideal for early-stage or low-dose research (2.5mg–5mg).

• 40mg Pen → Designed for advanced dosing protocols (2.5mg–10mg).